Omega-3 Anxiety Meta-analysis: What the Evidence Says

Quick Answer

Omega-3 Anxiety Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• These factors collectively contribute to the increased psychological health risks faced by these patients. [Tan Zuolin (2026); evidence level 1]
• Network meta-analysis allows both direct and indirect comparisons across multiple interventions, providing a more comprehensive evidence base (;). [Tan Zuolin (2026); evidence level 1]
• Given the modest efficacy of standard interventions, interest in well-tolerated, low-risk alternatives is increasing. [Fleig Katharina (2026); evidence level 3]
• Conversely, omega-3 PUFAs eicosapentaenoic acid (EPA; 20:5ω3), docosapentaenoic acid (DPA; 22:5ω3), and docosahexaenoic acid (DHA; 22:6ω3) are predominantly found in fatty marine fish and algae. [Fleig Katharina (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For omega-3 anxiety meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Tan Zuolin (2026). A network meta-analysis of interventions for anxiety and depression in PCOS. DOI: 10.7717/peerj.20744. PMCID: PMC12883158. PMID: 41664652. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12883158/
• Fleig Katharina (2026). Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential. DOI: 10.3389/fnut.2026.1748196. PMCID: PMC13082994. PMID: 42005438. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13082994/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.